Biotinylated Human IL-23 alpha&IL-12 beta Protein
Catalog No: IL23-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human IL-23 alpha&IL-12 beta Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus of IL-23 alpha. It contains amino acid residues Arg20-Pro189 (IL-23 alpha) and Ile23-Ser328 (IL-12 beta) (accession: Q9NPF7(IL-23 alpha) & P29460(IL-12 beta)).
Product Details
- Molecular Aliases
- IL23 alpha; IL12 beta; IL23 alpha&IL12 beta; IL12 β; IL23 alpha&IL12 β; IL-23A&IL-12B; IL23A&IL12B;IL12 b; IL12b; IL23 alpha&IL12 b; IL23 alpha&IL12b
- Protein Length
- Arg20-Pro189
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 21.7 kDa (IL-23 alpha) and 34.7 kDa (IL-12 beta). Due to glycosylation, the protein migrates to 24 kDa (IL-23 alpha) and 40-50 kDa (IL-12 beta) based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human IL-23 alpha&IL-12 beta on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human IL-23 alpha&IL-12 beta is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human IL-23 alpha&IL-12 beta, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human IL-23R, hFc Tag with the EC50 of 21.0ng/ml determined by ELISA (QC Test).
Immobilized Biotinylated Human IL-23 alpha&IL-12 beta, His Tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-IL-23 Antibody, hFc Tag with the EC50 of 2.3ng/ml determined by ELISA.
Immobilized Biotinylated Human IL-23 alpha&IL-12 beta, His Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Risankizumab, hFc Tag with the EC50 of 1.2ng/ml determined by ELISA.
Background
The interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn's disease (CD). Targeting this pathway has opened new avenues for therapeutic intervention. The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity.
References
- Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101604. doi: 10.1016/j.bpg.2019.02.006. Epub 2019 Feb 19. PMID: 31327402.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.